Corona Remedies Limited
2,043.80
INR
+22.90
(+1.13%)
ISIN
INE02ZQ01018
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Niravkumar Mehta
- Full Time Employees
- 5,153
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Ahmedabad India
- Website
- coronaremedies.com
- Similar Companies
- Business
- Corona Remedies Limited is an India-based pharmaceutical company engaged in the development, manufacturing, marketing, and distribution of branded pharmaceutical formulations. Founded in 2004 and headquartered in Ahmedabad, Gujarat, India, the company specializes in high-growth chronic, sub-chronic, and acute therapeutic segments. Its diversified product portfolio is organized across several core medical specialties, including Women's Healthcare, comprising hormonal therapies, fertility treatments, pregnancy support supplements, and gynecological formulations; Pain Management and Orthopedics, encompassing muscle relaxants, non-steroidal anti-inflammatory drugs (NSAIDs), and analgesic combinations; Cardio-Diabetic Care, featuring oral anti-diabetic medications, anti-hypertensives, and lipid-lowering agents; Urology, providing therapeutics for benign prostatic hyperplasia and urinary disorders; and General Therapeutics, covering gastrointestinal medications, respiratory formulations, and nutritional supplements such as vitamins, minerals, and nutrients (VMN). Key commercial brands include Myoril, a prescription muscle relaxant; Cortel, an anti-hypertensive range; Obimet, an oral antidiabetic therapy; Thyrocab, a thyroid management medication; alongside established formulations such as B-29, Tricium, Vitneurin, Stelbid, Dilo DX, and Dilo BM. Corona Remedies operates compliant manufacturing facilities located in Bhayla, Gujarat, and Solan, Himachal Pradesh, supporting solid oral dosages, liquids, and topical preparations under World Health Organization Good Manufacturing Practices (WHO-GMP) and European Union Good Manufacturing Practices (EU-GMP) standards. The company distributes its formulations across a widespread domestic network in India, targeting specialist medical practitioners, clinics, and hospitals in metropolitan, urban, and semi-urban centers, while maintaining export operations to select international markets across Southeast Asia, Africa, and Latin America. In recent corporate developments, Corona Remedies converted from a private entity into a public limited enterprise and completed its Initial Public Offering (IPO) in December 2025, listing its equity shares on the National Stock Exchange of India (NSE: CORONA) and the BSE Limited. The transaction provided a partial exit for private equity investor ChrysCapital, which held an equity stake through Sepia Investments. The company has aggressively pursued an inorganic expansion strategy to strengthen its core therapeutic verticals, highlighted by the strategic acquisition of the Myoril pain management brand from Sanofi, alongside the integration of established legacy brands acquired from multinational pharmaceutical corporations, including Abbott India and GlaxoSmithKline. Furthermore, Corona Remedies executed upstream strategic investments in active pharmaceutical ingredient (API) capabilities, acquiring an equity interest in hormone API producer La Chandra Pharmalab to ensure supply chain resilience and support its expanding women's healthcare portfolio.